Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Penicillin allergy

David J. McCullagh and Derek K. Chu
CMAJ February 25, 2019 191 (8) E231; DOI: https://doi.org/10.1503/cmaj.181117
David J. McCullagh
Divisions of Infectious Disease (McCullagh), and Clinical Immunology and Allergy (Chu), Department of Medicine, McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek K. Chu
Divisions of Infectious Disease (McCullagh), and Clinical Immunology and Allergy (Chu), Department of Medicine, McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Penicillin allergy is commonly reported, but 9 out of 10 times, penicillin will be tolerated if administered

About 10% of people report a penicillin allergy, but 90%–95% of those individuals are not truly allergic.1 Reasons for this include mislabelling intolerances as allergies and waning of immunoglobulin E–mediated allergy over time.2,3

The label of penicillin allergy is bad for patients and the health care system

More than just a problem for prescribers of antibiotics, the label of penicillin allergy is associated with the use of costly and less effective second-line and broad-spectrum antibiotics,1–3 a 55% increased risk of acquiring methicillin-resistant Staphylococcus aureus, and a 35% increased risk of Clostridium difficile infection (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.181117/-/DC1).4

Patients reporting penicillin allergy can be easily risk stratified to determine whether they require specialist evaluation

A known adverse effect of a penicillin (e.g., nausea) should not be documented as an allergy; likewise, avoidance of penicillin is unnecessary in those with a family history of penicillin allergy without a personal history of one, or in those who have since tolerated penicillin (low-risk). In those who have experienced severe delayed hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms or Stevens–Johnson syndrome and toxic epidermal necrolysis (high-risk), β-lactams should be strictly avoided; allergy skin testing is contraindicated. Patients reporting probable or unclear immunoglobulin E reactions that may present as rapid-onset urticaria, angioedema or anaphylaxis (intermediate risk) should be referred (Appendix 1).2,3

Penicillin allergy is lost over time, with resolution in 80% of people over 10 years, and in 50% over 5 years

Those with remote (> 10 yr) reactions are unlikely to still be allergic and should be tested before challenge with penicillin.1–3 If there is an acute indication for antibiotics, expert consultation is preferable to guide testing versus empiric therapy.

Allergy referral and testing is vastly underused, but is safe, accurate, rapid and cost-effective

Allergy testing over 1–2 hours using a combination of skin and challenge testing by trained personnel has been shown to be safe and effective for children, adults, inpatients and outpatients, with a negative predictive value close to 100%.1–3

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj

Footnotes

  • CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181117-five

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Sacco KA,
    2. Bates A,
    3. Brigham TJ,
    4. et al
    . Clinical outcomes following inpatient penicillin allergy testing: a systematic review and meta-analysis. Allergy 2017;72:1288–96.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Shenoy ES,
    2. Macy E,
    3. Rowe T,
    4. et al
    . Evaluation and management of penicillin allergy: a review. JAMA 2019;321:188–99.
    OpenUrl
  3. ↵
    Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259–73.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Blumenthal KG,
    2. Lu N,
    3. Zhang Y,
    4. et al
    . Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018;361:k2400.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (8)
CMAJ
Vol. 191, Issue 8
25 Feb 2019
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Penicillin allergy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Penicillin allergy
David J. McCullagh, Derek K. Chu
CMAJ Feb 2019, 191 (8) E231; DOI: 10.1503/cmaj.181117

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Penicillin allergy
David J. McCullagh, Derek K. Chu
CMAJ Feb 2019, 191 (8) E231; DOI: 10.1503/cmaj.181117
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Penicillin allergy is commonly reported, but 9 out of 10 times, penicillin will be tolerated if administered
    • The label of penicillin allergy is bad for patients and the health care system
    • Patients reporting penicillin allergy can be easily risk stratified to determine whether they require specialist evaluation
    • Penicillin allergy is lost over time, with resolution in 80% of people over 10 years, and in 50% over 5 years
    • Allergy referral and testing is vastly underused, but is safe, accurate, rapid and cost-effective
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Periorbital petechiae after emesis in a young woman
  • Gastroparesis
  • Oral ivermectin treatment for an infant with crusted scabies
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Allergy
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire